Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CCKBR | P32239 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787100 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL28478851 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL29630317 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL764194 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL17760630 | 1.00 | CYP2D6 (1.00) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL2215687 | 0.92 | CYP2D6 (0.85) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL17760541 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL32689432 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL32689431 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 | |
| SCHEMBL17760584 | 0.91 | CYP2D6 (0.83) | CYP2D6TSHRMAPK1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | CYP2D6 347/4885TSHR 1374/4885MAPK1 1141/4885 |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | CYP2D6 347/4885TSHR 1374/4885MAPK1 1141/4885 |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | HRAS, KRAS, NRAS | CYP2D6 3927/4885TSHR 4164/4885MAPK1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.